Pharmacogenomics. Companion Diagonostics. CTCBIOPSY Solutions. FISH Solutions

YZY MED specializes in providing comprehensive one-stop solutions for cancer management.

7200m² Self-owned Property

>40 Published Papers

160+ Licensed Products

>2.5 Million Tested Patients

Founded in 2011, with personalized diagnosis and treatment of cardiovascular, tumor as the strategic direction, Wuhan YZY Medical Science and Technology Co., Ltd. (YZY MED) is a high-tech enterprise specializing in the R&D, production and sales of individualized medical diagnostic products. The company has established various technical platforms, including ARMS fluorescence qPCR, multiple fluorescence qPCR, fluorescence in situ hybridization (FISH) and circulating tumor cell detection, etc. Meanwhile, the self-developed products include molecular diagnostic products to guide personalized medicine for cardiovascular and cerebrovascular diseases, companion diagnostic products to guide tumor diagnosis and treatment, FISH products and circulating tumor cell (CTC) autoanalyzer system, all these provide clinical diagnosis basis for precision medicine.

Various technical platforms

Self-developed products

Product Center

FISH Fully Automatic Slide Processing System F902

FISH Slide Processing System F901

FISH Auto Slide Processing System F900

FISH Hybridization System F10

Breast Cancer

Hematology

Lymphoma

“The right drug for the right patient”

YZY MED strives to become a leading enterprise in the field of personalized diagnosis and treatment.

Corporate Mission

The Right Drug for the Right Patient

Enterprise Vision

To become a leading enterprise in the field of personalized medicine. Create an excellent platform to realize self value to contribute back to society!

Core Values

Integrity, Proactive, Cooperation, Innovation

R&D Center

Vigorously advocate international cutting-edge personalized medicine, achieving a modern personalized treatment model

Leading Market Share in Molecular Diagnosis for Pharmacogenomics (PGx)

After more than 10 years of technology accumulation and clinical application, YZY MED has become the leading enterprise in pharmacogenomics in China, with a high market share. The company will continue to launch new products, aiming to consolidate the leading position in this segment.

Complete Target Certificates for Companion Diagonostics Reagents (CDx)

YZY MED is one of the enterprises with the most completent product line in companion diagonostics. Through continuous technology accumulation and market validation, the company has maintained rapid sales growth with more than 100,000 tests.

The First Autoanalyzer System on Circulating Tumor Cell (CTC) Certified in China

YZY MED is the first enterprise in China to carry out liquid biopsy technology. CTCBIOPSY® system is the first NMPA approved system in China with more than 50,000 clinical validation.The company continues to maintain its leading position in the field of liquid biopsy through continuous technology accumulation and clinical data.

YZY MED attaches great importance on innovation and R&D, R&D personnels account for more than 30%. It has applied for more than 110 patents, obtained over 70 patents authorized. The products have been sold to more than 20 countries and regions around the world, and have accessed into over 600 large and medium-sized hospitals with good market feedback, establishing an industry position in the field of personalized medicine.

Adhering to the mission of “The right drug for the right patient”, YZY MED strives to become a leading enterprise in the field of personalized diagnosis and treatment.

Certificate Center

Free Quote

We will be happy to help you with any questions about any product.

Get quick response

Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.

Phone/WhatsApp

+86 17720538289

Contact Us